SCIENCE@home

Trackable Tolerogenic Macrophages Integrate PD-L1 and Rapamycin Signaling to Suppress Alloimmune Responses in Transplantation.

Yihui Wang,Yuan Song,Yuji Xie,Junmin Zhang,Jing Liu,Wenyuan Wang,Ying Xu,Wenqian Wu,Wuqi Zhou,Qiaofeng Jin,Jing Wang,Yali Yang,Li Zhang,Tang Gao,Mingxing Xie

Published 2026 in Advancement of science

ABSTRACT

Cell-based immunotherapies represent a promising strategy for transplant tolerance, yet challenges remain in graft targeting, in vivo tracking, and comprehensive regulation of alloreactive T cells. Here, we developed trackable tolerogenic macrophages (TTMs), engineered to overexpress PD-L1, incorporate azide groups for bioorthogonal labeling, and encapsulate rapamycin nanoparticles (RAPA NPs). Following intravenous administration in murine allografts, TTMs preferentially homed to inflamed grafts and were visualized in vivo. TTMs reduced graft inflammation and prolonged allograft survival up to 35 days, significantly longer than PD-L1 or RAPA monotherapy groups. Mechanistic studies showed that PD-L1 ligation of PD-1 suppressed Th1 differentiation and CD8+ T-cell activation, reducing IFN-γ/TNF-α and thereby attenuating complement activation and PI3K/Akt/mTOR signaling. This enhanced rapamycin-mediated mTOR inhibition and promoted Foxp3+ Treg induction with increased IL-10 production. The elevated IL-10 further strengthened PD-1/PD-L1 signaling, forming a feedback loop that maintained a tolerogenic microenvironment. Together, these findings highlight TTMs as multifunctional therapeutic cells that integrate graft homing, real-time tracking, and dual-pathway immunoregulation to advance precision immunotherapy in transplantation.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-95 of 95 references · Page 1 of 1

CITED BY

  • No citing papers are available for this paper.

Showing 0-0 of 0 citing papers · Page 1 of 1